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Abstract
Intraoperative radiotherapy differs from conventional, fractionated radiotherapy in several aspects that may
influence its biological effect. The radiation quality influences the relative biologic effectiveness (RBE), and the role
of the five R’s of radiotherapy (reassortment, repair, reoxygenation, repopulation, radiosensitivity) is different.
Furthermore, putative special biological effects and the small volume receiving a high single dose may be
important. The present review focuses on RBE, repair, and repopulation, and gives an overview of the other factors
that potentially contribute to the efficacy. The increased RBE should be taken into account for low-energy X-rays
while evidence of RBE < 1 for high-energy electrons at higher doses is presented. Various evidence supports a
hypothesis that saturation of the primary DNA double-strand break (DSB) repair mechanisms leads to increasing use
of an error-prone backup repair system leading to genomic instability that may contribute to inactivate tumour
cells at high single doses. Furthermore, the elimination of repopulation of residual tumour cells in the tumour bed
implies that some patients are likely to have very few residual tumour cells which may be cured even by low doses
to the tumour bed. The highly localised dose distribution of IORT has the potential to inactivate tumour cells while
sparing normal tissue by minimising the volume exposed to high doses. Whether special effects of high single
doses also contribute to the efficacy will require further experimental and clinical studies.
Background
Technological advances in mobile radiotherapy (RT)
units have greatly increased the clinical application of
intraoperative radiotherapy (IORT) [1–4] by providing
highly localized beams of low-energy X-rays (LEX) or
high-energy (MeV) electrons. The physical radiation
qualities of these sources may differ to some extent from
that of high-energy photons (MeV X- or γ-rays) used in
conventional external beam RT, and thus potentially
influence the relative biologic effectiveness (RBE). Simi-
larly, differences in dose distributions will influence the
biological effects on residual tumour cells after excision
of the tumour and on normal tissue cells in the tumor
bed. Furthermore, delivering the total dose of adjuvant
RT in a single large fraction is a major departure from
conventional fractionated external beam RT with typical
daily fraction sizes of 1.8–2.0 Gy. The rationale for
fractionated RT is based on the four R’s of RT: reassort-
ment, repair, reoxygenation, and repopulation [5], to
which radiosensitivity was later added [6]. Reassortment
between fractions redistributes surviving cells over cell-
cycle phases thus avoiding repeated irradiation in resist-
ant phases. Repair influences the biological effects of
dose rate and time between fractions. Reoxygenation is
important for tumours containing acutely hypoxic frac-
tions of malignant cells. Repopulation decreases the
biological effect of RT with long overall treatment time,
and the radiosensitivity of tumour cells to different
single doses (i.e., the dose response) determines the bio-
logical effect when the fraction size is increased. In
addition, very large dose fractions may induce effects at
cellular, tissue, and systemic, levels that are different
from those seen after fractionated schemes with moder-
ate fraction sizes (1–3 Gy). Finally, the dose distribution
influences the biological effect on tumour cells and
normal tissue. Here we discuss these factors with an
emphasis on the biological effects of radiation quality,
repair, and the role of repopulation.
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Radiation quality
Currently, IORT is applied using isotropic fields of
50 kV X-rays or dedicated linear accelerators with paral-
lel electron beams of nominally 3–12 MeV [7]. The radi-
ation quality is characterized by the ionisation density
which is quantified by the linear energy transfer (LET)
[8]. Electrons and X-rays are low-LET radiations as
opposed to α-particles and heavy ions which are high-
LET radiations. The LET increases with decreasing
energy and thus the LET of LEX is higher than that of
high-energy electrons although both are low-LET radia-
tions with LET values 1–2 orders of magnitude lower
than that of high-LET radiation. [8–10]. LEX deposit a
higher proportion of their energy as electron track ends
with low energies (<1 keV) compared with high-energy
X-rays. Thus LEX will produce more lethal DNA lesions
(double-strand breaks, DSBs, and complex lesions) per
Gy resulting in an increased RBE [9–12].
The RBE of 50 kV X-rays from the Intrabeam® system
(Carl Zeiss Meditec AG, Jena, Germany) for cell inactiva-
tion in vitro was determined for irradiation in a tumour-
bed phantom. Irradiation at a distance of 8 mm from the
surface of a 4 cm spherical tumour-bed applicator showed
significantly increased RBE values relative to the reference
radiation of 6MV X-rays [13]. The RBE values were
comparable with that of a 50 kV surface X-ray unit and
various published studies using experimental LEX sources
[14–17] but was lower than the experimental values
reported for the Intrabeam predecessor source operated at
40 kV X-ray without an applicator [18].
The RBE is defined as the dose ratio of the reference
and test radiations producing the same biological effect:
RBE =Dref/Dtest. In terms of the linear-quadratic (L-Q)
formalism ln(SF) = −(α ×D + β ×D2) where SF is the sur-
viving fraction of cells, D is the single-fraction dose, and α
and β are the linear and quadratic coefficients, this implies
that RBE→ αtest/αref in the low-dose limit (D→ 0 Gy)
while the high-dose asymptotic limit will be RBE→ 1 if
the value of β is the same for the two radiations. Thus, for
high-LET radiation and LEX with RBE > 1, the L-Q for-
malism predicts a maximum RBE value at D = 0 Gy and a
decrease in RBE with increasing dose. However, Liu et al.
[13] found no significant dependence of RBE on dose indi-
cating an effect of RBE on both the linear and quadratic
components of the linear-quadratic model. This agrees
with previous RBE studies on low-LET radiations [14–17]
but contrasts with the assumptions of the L-Q model that
the radiation quality affects mainly the linear term repre-
senting irreparable lesions [19, 20]. On the other hand, a
study on monoenergetic 8 keV photons was consistent
with the L-Q assumption of an effect on the linear compo-
nent and showed further radiobiological effects reminis-
cent of high LET [21]. The latter is unexpected because
photoelectrons released by interactions of photons with
water and other molecules in the cells should not be
different from track-ends of electrons with higher initial
kinetic energy. These apparently conflicting result
might be reconciled if a proportion of the absorption
events of 8 keV photons result in emission of highly
localized low-energy Auger electrons that produce
more complex damage [22–24].
The unfiltered energy spectrum from Intrabeam in-
cludes a substantial contribution of low photon energies
which are filtered over the first 1–2 cm of water-
equivalent material resulting in hardening of the beam
within the spherical applicators [9, 25]. Whether further
beam hardening occurs in the tumour bed targeted by
IORT is unclear but attenuation of the radial dose func-
tion for 50 kV X-rays is nearly constant at 2.0–3.5 cm
radial distance from the source suggesting no gross
change in radiation quality [9].
Because the energy of MeV electron beams is usually
higher than the mean energy of secondary electrons pro-
duced when 6MV X-rays interact with water or tissue,
the RBE of high-energy electrons may be slightly lower
than that of X-rays. RBE values of 0.9 ± 0.1 for 11 MeV
electrons relative to 60Co γ-rays (E = 1.25 MeV) have
been published [17] but the RBE relative to 6MV X-rays
used in modern external beam RT has not been deter-
mined so far. Therefore, we measured the RBE of 10 MeV
electrons from a linear accelerator for cell survival in vitro.
Survival of V79 cells showed no difference between
10 MeV electrons and 6MV X-rays at doses up to 6–8 Gy
but an increase of surviving fractions (SF) was suggested in
the dose range 10–12 Gy (Additional file 1: Supplementary
Material and Additional file 2: Figure S1A). This trend was
confirmed in independent experiments where the dose was
extended to 14.3–17.1 Gy yielding an RBE value of 0.94 ±
0.02 (P = 0.04, n=3) at SF = 0.0003. For MCF7 breast cancer
cells (Fig. 1a, Additional file 2: Figure S1B) no significant
difference was observed up to 11.4 Gy (RBE = 0.98 ± 0.01,
P = 0.10, n=3) at SF = 0.0003 but normal human umbilical
vein endothelial cells (HUVECs; Fig. 1b and Add-
itional file 2: Figure S1C) showed significantly de-
creased values of RBE = 0.93 ± 0.02 (P = 0.005, n = 6)
at SF = 0.03 (mean electron dose 5.8 Gy) and RBE =
0.91 ± 0.02 (P = 0.015, n = 3) at SF = 0.005 (mean elec-
tron dose 8.7 Gy). However, the data seemed to indi-
cate an effect on the quadratic term which is
considered to represent potentially lethal but
reparable lesions [26]. Thus, overall the RBE of
10 MeV electrons was only moderately or not signifi-
cantly reduced relative to 6MV X-rays in the three
cell lines tested. This supports clinical practice from
fractionated RT assuming RBE = 1 for electrons given
in standard fraction sizes. The fact that a reduced
RBE was only detected at higher doses may either
simply reflect the different slopes of the survival
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curves or possibly indicate a role of reparable dam-
age in the RBE of low-LET radiations. Whether the
apparent difference between MCF7 and HUVEC is
characteristic for tumour and normal cells will re-
quire further studies.
It is important to note that differences in the RBE of
low-LET radiations with different beam energies do not
influence the quality of different IORT modalities per se.
Although the yield of lethal lesions per Gy will differ,
doses from different radiation qualities may be com-
pared by multiplying the physical dose with the RBE to
give the isoeffective dose of the reference radiation.
However, the types of lesions are the same since the
ionisation tracks are produced by the same kind of parti-
cles, namely primary or secondary electrons. This con-
trasts with high-LET radiations such as C-ions, which
produce a dense track of ionisations resulting in mainly
complex, irreparable lesions.
Reassortment
Cellular radiosensitivity varies through the cell cycle, with
mitosis and late G1 phase being sensitive while the late
synthetic (S)-phase is relatively resistant [8]. Thus surviv-
ing cells after irradiation of asynchronous cell populations
will be enriched in the more resistant phases. During frac-
tionated radiotherapy of tumours with rapid cell prolifera-
tion, heterogeneity in cell cycle kinetics will redistribute
(reassort) cells over the cell cycle between daily fractions
[27]. Obviously, reassortment does not play a role in IORT
with a single dose. However, single-dose cell survival
curves show no evidence of a resistant subpopulation
which should manifest itself by a decreased slope at higher
doses similar to that observed for hypoxic subpopulations
[8]. Obviously the increased efficacy of incremental doses
suffices to compensate the increase in radioresistance
caused by the stronger inactivation of radiosensitive cell-
cycle phases. Some potential mechanisms contributing to
high-dose radiosensitivity will be discussed below.
Repair – dose dependence
While the induction of DSBs is proportional to dose, the
repair system may conceivably become saturated at
higher doses. Saturated repair has been suggested to
explain the downward curvature of low-LET cell survival
curves [28, 29]. Mammalian cells repair DSBs mainly by
non-homologous end-joining (NHEJ) which is the primary
DSB repair mechanism in all cell-cycle phases and rejoins
double-stranded DNA ends without requirement for hom-
ology [30, 31]. A smaller fraction of DSBs is repaired by
homologous recombination (HR) which is error free but
requires a sister chromatid strand as template and thus is
active only in late S and G2 [30, 32, 33]. Rejoining of
‘simple’ DSBs in euchromatin is performed by NHEJ with
fast kinetics while DSBs in heterochromatin, and complex
DSBs which failed to be repaired by NHEJ, are repaired by
HR with slow kinetics [30, 34, 35].
Induction and repair of DSB can be monitored by anti-
bodies against phosphorylated histone γH2AX which
marks DSB sites and acts as scaffold for the DSB repair
machinery. Induction of γH2AX foci occurs within mi-
nutes after irradiation and reaches its maximum at ap-
proximately 30 min (Additional file 1: Supplementary
Material and Additional file 2: Figure S2A). This method
can detect DSBs after doses in the range 0.001–2 Gy and
showed similar yields of foci per Gy as for physical DSBs
measured in the range 10–100 Gy in human fibroblasts
[36]. However, a sub-linear increase in the number of
γH2AX foci at doses higher than 2–3 Gy has been de-
scribed for different cell lines [37, 38]. This did not appear
to be caused by overlapping foci imposing an upper limit
for detection of individual foci. First, cell types with differ-
ent yields of foci per Gy showed similar sub-linearity even
at dose levels where foci were not overlapping. [38, 39].
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Fig. 1 Survival curves for irradiation of cells in vitro with 10 MeV electrons (20 mm water-equivalent depth) or 6 MV X-rays. The RBE of
electrons was not significantly different from 1 (RBE = 0.98 ± 0.01; P = 0.10, n = 3) for MCF7 cells (a) while RBE was significantly reduced
(RBE = 0.91 ± 0.02, P = 0.015, n = 3) after irradiation of HUVEC with higher doses (b). These experiments corroborated trends observed in
independent experiments at lower doses (Additional file 2: Figures S1B, C)
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Second, the distribution of foci in individual cells was not
skewed towards high numbers as expected if an upper
limit is reached (Additional file 2: Figure S2B-E). Third,
the deviation from linearity 240 min after irradiation was
observed at approximately the same dose as at 30 min, in
spite of a much lower mean number of foci after repair
(Fig. 2a). Similar observations were made with MCF7 and
HUVECs (Additional file 2: Figure S3A, B), and with hu-
man skin fibroblasts (Herskind et al., manuscript in prep-
aration). Further evidence indicated that the fraction of
remaining foci was lower at low dose and increased with
dose, suggesting that the rate of foci decay is reduced at
higher doses (Additional file 2: Figure S3C). This supports
the hypothesis that a saturated repair process, rather than
optical overlap of foci, is involved in the non-linear dose
response.
Most studies have found DSBs to be repaired with bi-
exponential kinetics representing the fast and slow com-
ponents, although a third, even faster component with
halftime <5 min has been described [40, 41]. Physical
methods for measuring DSBs have shown a high
capacity for fast rejoining which starts immediately after
irradiation and repairs more than 50% of the DSBs
before induction of γH2AX foci reaches its maximum
[42–45]. This might be explained if the foci are too small
to be detected by immunofluorescence microscopy or are
quickly resolved [40, 42, 46]. However, high-resolution
studies using transmission electron microscopy (TEM)
showed that NHEJ-mediated repair of DSBs (marked by
pairs of Ku70 protein binding to the DNA double-strand
ends) occurred with fast kinetics in euchromatin and was
not associated with DNA repair foci in contrast with DSBs
in heterochromatin which were associated with DNA
repair foci and were repaired with slow kinetics [47, 48].
Further evidence showed that foci may combine with
neighbouring foci at distances up to 1–2 μm indicating
the formation of repair centres [49]. This may explain a
previous observation that the linear range of the γH2AX
dose response at low doses was extended to higher doses
before the transition to sublinearity when the integrated
fluorescence intensity was detected by flow cytometry
compared with microscopic counting of foci numbers
[38]. The decay of γH2AX foci after 30 min could be
fitted by bi-exponential kinetics although the data
were also compatible with a hyperbolic fit (Additional
file 2: Figure S4). The decay of γH2AX foci usually
occurs more slowly than physical DSB repair, which
has been suggested to be related to limited phosphat-
ase activity required for their resolution, and to foci in
heterochromatin which are formed and resolved more
slowly than in euchromatin [40, 42]. The observation
from TEM studies that some foci remained at late
times without evidence of DSBs suggested that they
may mark epigenetic changes in chromatin structure
[47]. Nevertheless, it also seems possible that repair
centres processing several DSBs will persist until the
last local DSB is repaired, and thus decay more slowly
than expected from the repair of individual DSBs. The
notion of repair centres would seem consistent with
the observation of foci containing more than a single
DSB in TEM studies [47, 48].
Formation of repair centres would contribute to reduce
the number of foci (though not their integrated intensity)
at 30 min. If availability of the DSB repair machinery is
limited, this might conceivably impose a limit on the rate
at which DSBs can be processed. Indeed, previous evi-
dence suggested that HR is saturated at high doses with
an increasing majority of DSBs being repaired by NHEJ
[33]. An error-prone alternative end joining (alt-EJ) path-
way has been proposed to act as a backup repair mechan-
ism for NHEJ [50, 51]. In contrast with classical NHEJ, in
which the Ku70/Ku80 heterodimer and DNA-PKcs stabil-
ise the DSB ends which are then processed and finally
ligated by LIG4/XRCC4, alt-EJ uses proteins otherwise
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Fig. 2 Sublinear dose response for the mean number of γH2AX foci per cell (V79) at maximum induction and after 4 h repair (30 min and
240 min post-irradiation, respectively) (a). Reduced colony size of V79 cells irradiated 14.3 Gy but not 5.7 Gy (10 MeV electrons, 20 mm water-
equivalent depth) (b)
Herskind et al. Radiation Oncology  (2017) 12:24 Page 4 of 14
involved in DNA metabolism. Thus PARP1 and WRN
stabilise the free ends which are ligated by LIG3/XRCC1
or LIG1 after processing of the ends [50]. Cumulative
evidence supports the view that this does not represent a
distinct DSB repair pathway but rather a means of remov-
ing free DNA ends left unrepaired by NHEJ and HR [50].
Furthermore, alt-EJ is associated with increased chromo-
some translocations which are normally suppressed by
NHEJ [51–53]. Thus, in the present context, we propose
that saturation of HR and overloading of the NHEJ path-
way result in increased use of the alt-EJ pathway and
increased chromosomal instability at higher doses. The
small size of colonies formed after 14.3 Gy but not 5.7 Gy
may indicate genetic instability of surviving cells after high
doses (Fig. 2b). A model of changing DSB repair pathway
usage at high single doses is summarised in Fig. 3.
Repair – protracted irradiation and fractionation
Recovery of cells between fractions is an important fac-
tor in fractionated RT. When irradiation of cells is split
into two doses, e.g., a fixed dose D1 and a variable dose
D2 separated by a time interval, T, the surviving fraction
(SF) will be higher than when given as a single dose, D1
+ D2. If the time interval is increased to allow complete
repair, the shape of the survival curve for the second
irradiation will approach that of the single-dose survival
curve starting at a lower survival level, SF(D1). Fre-
quently, such split-dose recovery is ascribed to repair of
socalled ‘sublethal damage’ (SLD) [8]. Continuous irradi-
ation with constant dose rate may be viewed as multiple
small fractions given at short intervals thus providing
the basis for the reduced biological effect of protracted
irradiation. The biological effect of incomplete recovery
between fractions or continuous low dose-rate irradi-
ation can be calculated using mathematical models
assuming monoexponential SLD repair [26, 54, 55]. In
order to account for a decreasing rate of SLD repair,
reciprocal recovery kinetics has been proposed, which
has the advantage that just two free parameters need to be
fitted compared with four parameters of a bi-exponential
model [56, 57], thus providing a more robust fit requiring
fewer data points.
Although DSB repair by HR or NHEJ has been impli-
cated in SLD repair [58–61], the relative importance of
the two mechanisms, and their relation to the biophys-
ical models, is not clear. For normal tissue, recovery kin-
etics derived from fractionation studies show halftimes
of approximately one hour or longer [62]. However, early
normal-tissue reaction in experimental systems yielded
shorter halftimes of 0.3–0.8 h [63], and some clinical
and experimental studies on early and late reaction
showed biphasic recovery with halftimes of 7–20 min
and 1.2–6.6 h for the fast and slow components, respect-
ively [64–67]. For tumour cells, most evidence suggests
a single-component halftime of the order of one hour
[62]. However, other studies have found shorter recovery
halftimes in the range 5–50 min [68] or 23 min with
some evidence of bi-exponential recovery with halftimes
of 18 and 96 min [69].
For IORT given as protracted irradiation with Intra-
beam, the L-Q model predicts that SLD repair should
reduce the biological effect of higher doses [9, 70]. Since
protracted IORT with Intrabeam typically requires 20–
50 min, only recovery within this post-irradiation time
frame is relevant. Split-dose experiment with V79 ham-
ster and MCF7 human breast cancer cells yielded half-
times of 15 min and 39 min, respectively (Additional
file 1: Supplementary Material and Additional file 2:
Figure S5). For V79 cells, a slower rate of repair was
indicated after 1–2 halftimes. Previous modelling calcu-
lations of the biological effect of SLD repair for pro-
tracted irradiation with Intrabeam used the L-Q
formalism and assumed halftimes of 15 min as a con-
servative limit for fast repair [25, 69–71]. The present
values together with the evidence from literature
supports the use of this conservative value and suggests
that the effect of recovery may be smaller if halftimes
are longer, although recovery halftimes are short
enough relative to the irradiation times for IORT that
they should be taken into account.
The L-Q formalism is used to model effects of changes
in fractionation and dose rate. The underlying α/β
NHEJ
HR alt-EJ
Complex
DSBs
High 
doses
accurate deletions chromosomal
instability
DSB
Fig. 3 Proposed schematic model of increasing use of alternative
end joining (alt-EJ) leading to increased chromosomal instability at
higher doses. HR: homologous recombination. NHEJ: non-
homologous end joining. Modified after Shibata and Jeggo [30]
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parameter describes the downward curvature of single-
cell survival curve and the sensitivity to changes in frac-
tion size [63]. However, it should be noted that α/β for
fractionation is determined from fractionation studies
with full recovery between daily fractions, and not from cell
survival curves. For local control after breast RT, the most
recent estimate is α/β = 4 Gy (c.i. 0.0–8.9 Gy) at median
9.3 years follow-up with some evidence that it may even be
slightly lower [72]. This is comparable with α/β for late
normal-tissue (NT) reaction (shown in Table 1) leading to
the conclusion that the therapeutic window between
tumour control and adverse effects depends less on fraction
size than previously assumed [73, 74].
Reoxygenation
Oxygen is a radiosensitizer of cells owing to its ability to
fix DNA damage which may otherwise be chemically
repaired by intracellular antioxidants under hypoxia [8].
Thus the cellular radiosensitivity is reduced under
hypoxia. Some tumors contain chronically or acutely
hypoxic subpopulations requiring 2- to 3-fold higher
doses for inactivation [8]. Reoxygenation of acutely hyp-
oxic cells between daily fractions is an important aspect
of fractionated radiotherapy. In tumour-bed IORT, the
bulk tumour has been removed by surgery and thus only
microscopic clusters of tumour cells should be present
in the healthy tumour bed. Under most conditions, it
seems reasonable to assume that these cells will have an
adequate supply of oxygen. However, care should be
taken not to compress the tumour bed too strongly
during IORT with LEX or otherwise compromise the
blood supply to an extent that might induce hypoxia in
the tumour-bed tissue.
Repopulation
An important aspect of IORT is that irradiation takes
place immediately after tumour excision thus avoiding
repopulation of remaining tumour cells during the time
between surgery and conventional external beam radio-
therapy. Although EBRT should begin as soon as pos-
sible, a five-week period for wound healing is required
before starting EBRT in order to avoid excessive normal-
tissue reaction [75]. A systematic review showed that
delaying EBRT for more than 8 weeks in breast cancer,
and more than 6 weeks in head and neck cancer, re-
sulted in increased recurrence rates, emphasizing the
importance of repopulation after surgery in these
tumours [76, 77]. Furthermore, in the START B frac-
tionation trial, recurrence rates were reduced (though
not significantly) when hypofractionated EBRT (15 ×
2.67 Gy) was given over three weeks compared with five
weeks in in the conventional arm (25 × 2.0 Gy, EQD2 =
50 Gy where EQD2 is the equivalent dose given in 2 Gy
fractions) [72]. This observation was in spite of the
equivalent total dose, EQD2, being lower in the acceler-
ated, hypofractionated arm: EQD2 = 44.5 Gy if given in
2 Gy fractions (assuming α/β = 4 Gy). The efficacy of the
shorter overall treatment time strongly suggests that
repopulation between fractions plays an important role
and could be equivalent to a daily dose of 5.5 Gy/14d =
0.4 Gy per day1. The increased recurrence rate observed
for the post-pathology stratum in the TARGIT trials for
patients treated some weeks after surgery compared with
patients irradiated during the surgical session [78] may
be explained by repopulation. Thus a major advantage of
IORT for fast proliferating tumours seems to be the
elimination of repopulation by the extreme shortening
of the overall treatment time. Since conventionally frac-
tionated EBRT cannot be completed earlier than ten
weeks after surgery (five weeks delay after surgery plus
five weeks of treatment), the associated benefit might
potentially be equivalent to a dose of the order of
28 Gy (70d × 0.4 Gy/d). This might even be a conserva-
tive estimate as it assumes the same rate of repopula-
tion during the delay as during RT, and does not
include additional time for a tumour boost given after
whole-breast RT. Further studies of the influence of
overall treatment time in fractionated radiotherapy
should be performed to validate this hypothesis and
provide more accurate estimates of the dose equivalent
of repopulation in different tumours.
Radiosensitivity
The risk of recurrence after RT depends primarily on
the number of surviving tumour cells capable of regrow-
ing the tumour. According to the cancer stem cell
hypothesis, only a subpopulation of tumour cells have
unlimited capacity for proliferation and it is generally
considered that these cells are more resistant to radi-
ation [79]. Cellular radiosensitivity is determined by the
colony formation assay (CFA) which scores the ability of
cells to produce clones with at least 50 cells correspond-
ing to > 5–6 cell doublings. Although the CFA is the gold
standard for determining radiosensitivity in vitro, detec-
tion of SF values <10−3 is notoriously difficult and
Table 1 α/β ratios for different normal-tissue end points
End point α/β 95% c.i. Ref.
Breast shrinkage 3.5 Gy 0.7; 6.7 Gy [72]
Breast induration 4 Gy 2.3; 5.6 Gy [72]
Telangiectasia 3.8 Gy 1.8; 5.7 Gy [72]
Breast oedema 4.7 Gy 2.4; 7.0 Gy [72]
Skin fibrosis 1.7 Gy 0.6; 2.6 Gy [146]
Telangiectasia 2.6–2.8 Gy see references in [147]
Pneumonitis 4.0 Gy 2.2; 5.8 Gy [148]
Lung fibrosis (radiol.) 3.1 Gy −0.2; 8,5 Gy [149]
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ultimately is limited by the number of cells which can
reasonably be seeded in the assay. In most cases the
conditions of the assay will not be constant, either
because increasing numbers of cells per flask or dish are
seeded to keep the number of colonies constant with in-
creasing dose, or because more cells are produced dur-
ing incubation of unirradiated compared with irradiated
cultures, in the case where constant numbers are seeded
and the number of colonies decreases with increasing
dose.
Although it is usually assumed that surviving colony-
forming cells are identical to unirradiated cells, this may not
be true in genetically instable tumour cells irradiated with
high doses. As argued above, high doses of radiation may in-
duce increased genetic instability, and certainly the colonies
scored at high doses are morphologically different from
those formed in unirradiated cultures. Thus genetic instabil-
ity may influence not only the number but also the proper-
ties of surviving cells. Furthermore, the shape of the survival
curve at high doses may be influenced by the number of
cells seeded in the CFA, suggesting that non-targeted cohort
effects play a role in cell inactivation by high doses [80].
Extrapolation of SF data to high doses used in IORT
or stereotactic radiosurgery has been a matter of debate.
It has been argued that cell survival curves have a linear
slope at high doses and various modifications of the L-Q
model, or alternative models, have been proposed to
account for this [81–85]. On the other hand, there is
evidence that the L-Q model fits quite well up to doses
of approximately 15 Gy [86] and, despite trends in good-
ness of fit to the experimental data, a significant differ-
ence between fitting the L-Q model and alternative
models has not been demonstrated [87–90]. In fact the
values of fit parameters are at least as important as the
choice of model for extrapolation [87, 91]. As argued
above, various experimental and environmental factors
may influence survival after high doses. Thus while
tumour cell transplantation and in-vivo tumour-cell
survival experiments reportedly produce linear survival
slopes at high doses [92], actual survival levels in an
IORT setting can only be estimated. A pragmatic ap-
proach, therefore, is to use the least complicated model
with the lowest number of free parameters (e.g., the L-Q
model) as a first approximation and closely monitor
patients with an aim of establishing dose-response rela-
tionships from clinical data. It should also be noted that
for non-uniform dose distributions such as the isotropic
X-ray field from Intrabeam with its steep gradient, a 10%
variation in dose only displaces the isodose curves by
approximately 1 mm [13, 70].
Other biological effects
In addition to clonogenic inactivation of tumour cells,
RT excerts effects on the stroma, vasculature, and the
immune system, that might influence the response of
residual tumour cells. Radiation induces expression of
inflammatory cytokines via NF-κB [93, 94], and cyto-
kines in wound fluid collected from breast cancer pa-
tients treated with IORT were implicated in biological
effects on migration and invasion of cancer cells [95]
though it is unclear if proliferation was inhibited [96]. Fur-
thermore, irradiation of endothelial cells can induce platelet
adhesion and thrombus formation in the microvasculature
[97, 98]. An overview of experimental studies on radiation-
induced vascular damage was published recently [99].
A series of papers have implicated the second messenger
ceramide in radiation-induced apoptosis of microvascular
endothelial cells. Ceramide may be released from the
membrane lipid sphingomyelin by the enzyme acid
sphingo-myelinase (ASMase), and activation of ceramide
synthase (CS) can lead to de novo synthesis of ceramide
[100, 101]. ASMase-dependent apoptosis of ASMase - rich
microvascular endothelial cells was proposed to constitute
the primary target for radiation-induced intestinal damage
after doses larger than 13–15 Gy while activated CS
contributed to apoptosis at doses above 18–20 Gy [102,
103]. The protective effect of an anti-ceramide antibody
strongly supported the proposed role of ceramide-induced
endothelial damage in the radiation gastrointestinal syn-
drome [104]. Furthermore, endothelial apoptosis of the
tumour vasculature was suggested to play an important
role in radiation-induced tumour control after single
doses of 15 Gy and more [105, 106]. Thus DNA damage-
mediated inactivation of clonogenic normal or tumour
stem cells (dominant at lower doses) and endothelial
apoptosis (at higher doses) was proposed to constitute a
two-target model for normal tissue damage and tumour
inactivation after high doses per fraction [102, 103, 106,
107]. However, these findings have been disputed and
remain controversial as they have not been reproduced in
other laboratories [87, 108–110].
Radiation is an efficient modulator of the immune
response and thus may have systemic effects that eventu-
ally help eliminate residual tumour cells. Higher radiation
doses (>5 Gy) result in increased tumour cell necrosis and
antigen presentation, and recruitment of T-cells to irradi-
ated and possibly distant unirradiated tumours (for re-
views see [9, 87]). In the setting of tumour-bed IORT,
most patients will have no residual tumour cells while in a
minority of patients the number of residual tumour cells
will vary between very few and perhaps up to some 105
cells in microscopic foci. Whether low numbers of tumour
cells suffice to elicit an antitumour response, and whether
a single high dose is more efficient than fractionated RT, is
not known and will require more studies. Thus, in spite of
a growing awareness of the importance of radiation in
stimulating the immune system, it is not clear if it contrib-
utes to the efficacy of high single doses.
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Irradiated volume, local control and normal-tissue reaction
An important aspect of IORT, and more generally of ac-
celerated partial breast irradiation (APBI), is the smaller
volume exposed to high doses compared with whole-
breast EBRT. The dose distribution varies between the
different modalities for delivering IORT. Thus tumour-
bed irradiation with LEX using spherical applicators to
fit the cavity left by the excised tumour yields a non-
uniform, isotropic dose distribution determined by a
combination of the distance-squared relationship and
beam attenuation. IORT with electrons (IOERT) delivers
high-energy electrons in a parallel beam with a charac-
teristic depth dose profile and range that depends on the
chosen beam energy. A comparison of dose distributions
from LEX, MeV electrons, and other IORT/APBI tech-
niques, was published by Nairz et al. [111]. Conformality
to the tumour bed may be an issue with both IORT
techniques. For LEX, conformality depends on the fit of
the tumour cavity to the spherical applicator, while the
choice of applicator size and the incident angle is critical
for covering the target volume treated by IOERT [111].
To treat other targets than the tumour bed around a
spherical cavity with LEX, new Intrabeam applicators
have been developed to irradiate intracavitary cylindrical
targets and targets with flat geometries [112–115].
For the non-uniform dose distribution of isotropic
LEX, radiobiological modelling of local control for
tumour-bed IORT of the breast suggested that inactiva-
tion of recurrence-forming foci close to the applicator
surface was more efficient than for external-beam radio-
therapy (EBRT) with a uniform dose to the whole breast.
The increased inactivation partly compensated the re-
duced inactivation at larger depth in the tumour bed
thus defining a ‘Sphere of Equivalence’ within which the
recurrence rate would be the same as for EBRT [71].
Nevertheless, the legitimate question arises whether
doses applied by LEX are sufficient to control residual
tumour cells at larger depth in the tumour bed where
the physical dose is reduced to approximately 6–7 Gy in
1 cm depth and 2–3 Gy in 2 cm depth depending on the
applicator size. By comparison, the dose distribution
for IOERT is rather uniform up to the penetration
depth determined by the beam energy and within the
area covered by the applicator size outside which the
dose decreases to virtually zero. However, after exci-
sion of the primary tumour the majority of patients de-
velop no recurrences and the number of residual
recurrence-forming tumour cells in patients who go on
to develop local recurrence is likely to show wide vari-
ation ranging down to just a few cells. This implies
that even low to moderate doses of radiation may con-
tribute to local control as long as the tumour is excised
with sufficient free margin leaving no solid tumour
mass [9, 116].
The rationale of IORT for early breast cancer is based
on studies showing that most ipsilateral recurrences
occur close to the site of the primary tumour and that
more distant recurrences may be considered new
primary tumours with a more favourable prognosis
[117–119]. Thus clinical studies testing the equivalence
of IORT as sole treatment with conventional EBRT
should be judged not only based on their dose distribu-
tions but should be considered a test of a hypothesis
involving several elements: 1) local distribution of
recurrence-forming residual tumour cells; 2) dose distri-
bution; 3) single-dose versus fractionated irradiation; 4)
total time between surgery and completion of RT; 5)
patient selection. Comparing the TARGIT trial using
non-uniform LEX and the ELIOT trial using IOERT, the
former was a risk-adapted approach where low-risk
patients were selected based on established risk factors
and postoperative EBRT was added to the treatment
based on the pathological findings. This constrasts with
ELIOT in which unselected patients received IOERT
with a nearly uniform dose distribution. Conformality of
the cavity to the spherical applicator is important for dose
coverage of the tumour bed in the TARGIT trial. In EL-
IOT, the choice of applicator size is critical for covering
the target volume [120–123].
Both randomized trials were within the pre-defined non-
inferiority margins for ipsilateral recurrence [78, 123].
However, increased recurrences were observed in the post-
pathology IORT stratum of the TARGIT trial [78] suggest-
ing that it is essential to perform IORT immediately after
surgery and not delayed in a second surgical session. In EL-
IOT, recurrences in the IOERT arm were associated with
unfavourable characteristics (tumour size ≥2 cm; ≥ 4
positive lymph nodes, grade 3 differentiation, estrogen
receptor-negative and triple-negative tumours), suggesting
that improved patient selection might reduce the recur-
rence rate after IOERT [123]. While differences in selection
criteria, treatment strategies, and median follow up,
hamper a direct comparison between the two IORT mo-
dalities, a critical analysis of the outcomes has been pub-
lished [121, 122]. Excluding the unfavourable subgroups
(pre-pathology treated patients in TARGIT, patients with
unfavourable characteristics in ELIOT) yielded 2.1% local
recurrence in TARGIT and 1.5% in ELIOT [78, 123]. Thus
at present, there is no evidence to suggest that differences
in the dose distributions affect the outcome.
IORT is frequently used as an intraoperative boost
combined with conventional EBRT for breast conserving
therapy. For IORT with non-uniform LEX, the full dose
of IORT is applied while the total dose of EBRT is usu-
ally reduced slightly from 50 Gy to 46 Gy. For IOERT
with uniform dose distribution, the IOERT dose is re-
duced to 8–10 Gy followed by standard EBRT (although
in the ELIOT trial EBRT was given after full-dose
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IOERT in patients with ≥4 positive lymph nodes [123]).
For both modalities, very high local control rates have
been reported in non-randomised series [124–127]
suggesting a clinical benefit of eliminating time for re-
population (‘temporal miss’) and reducing geographic
miss. However, conclusions regarding potential superior-
ity of an IORT boost over a conventional postoperative
boost must await long-term follow-up of randomized
trials [4].
The dose of RT that can be applied to inactivate re-
sidual tumour cells is limited by toxicity in the irradiated
normal tissue. With Intrabeam, skin toxicity is avoided
by keeping a distance >5 mm between the skin and the
applicator surface [75]. Radiobiological modelling of late
reaction suggested that pneumonitis is limited to dis-
tances ≤8–12 mm from the applicator surface so that
the thickness of the thorax wall should be sufficient to
shield the lung from the irradiation [70]. The risk of
fibrosis in the subcutaneous tissue was estimated to be
limited to 3–6 mm from the applicator surface [70, 128].
These estimates are likely to be further reduced by the
volume effect of late-reacting normal tissues. Thus the
tissue tolerance is increased when the volume exposed
to critical doses is reduced [129, 130] although recent
evidence suggests that the effect may be weak for breast
fibrosis [131]. Pneumonitis has not been reported for the
TARGIT trial but the ELIOT trial found less lung tox-
icity in the IOERT compared with the EBRT arm and
similar rates of breast fibrosis in the two arms [123].
Overall, the rate of fibrosis after risk-adapted IORT
with Intrabeam was similar to that after EBRT but sub-
analysis showed that it was associated with higher rates
after IORT as a boost in combination with postopera-
tive EBRT and lower rates after IORT alone [132]. Thus
only 5.9% of patients treated with IORT alone devel-
oped clinical fibrosis of the breast at 36 months [132]
consistent with the estimates from radiobiological mod-
elling discussed above. The most frequent wound-
related complications after IORT with Intrabeam are
hematomas and seromas but the rate is not higher than
after EBRT [78, 133].
For IORT given as a boost, previous work from our
department showed that the risk of late reaction after
EBRT is increased if the interval between surgery/IORT
and EBRT is shorter than five weeks [75]. For IORT
boost with LEX, moderate to severe fibrosis at 36 months
follow-up was observed in 43 and 31% of the patients
treated with an intervals shorter and longer than 5-
week, respectively [132]. The latter value may be com-
pared with rates of approximately 20% at 3 years, rising
to 28.1% at 10 years and 30.4% at 20 years, in the
EORTC boost trial [134–136] and with approximately
25% at 5 years for a boost in the 25 × 2 Gy control arm
of the START pilot trial [131]. Although the fibrosis
rates after an IORT boost appears somewhat increased
relative to a standard fractionated EBRT boost of 16 Gy,
it compares favourably with the higher rates of 40–55%
observed after a boost dose of 26 Gy in the EORTC
boost trial [136]. However, a direct comparison of an in-
traoperative versus conventional postoperative boost will
only be possible after long-term follow-up of the on-
going randomised TARGIT B trial.
A potential concern for high single-dose irradiation is
the risk of tissue necrosis and rib fracture. Fat necrosis
after IORT for breast cancer is found by diagnostic im-
aging although it is usually non-symptomatic [137, 138].
Rib fracture has been described after IOERT but is
avoided by introducing lead shielding of the ribs [139].
Brain necrosis can occur after high local doses,
dependent on the irradiated volume [140, 141], and
should be considered when applying IORT to the brain
[142]. In studies with typical target volumes in stereotac-
tic radiosurgery, the risk has been shown to be predicted
by the volume receiving a dose ≥ 12 Gy (V12Gy) although,
for larger target volumes, V10Gy may be a better pre-
dictor [143–145]. Because of the strong increase in
symptomatic radionecrosis with increasing volume, it
was suggested that patients with V10Gy > 10.5 cm
3 or
V12Gy > 8 cm
3 be considered for hypofractionated rather
than single-dose treatment [143].
Conclusions
A schematic overview over the different biological as-
pects of IORT with high single doses is shown in Fig. 4.
IORT is usually performed with different radiation qual-
ities than high-energy X-rays used in conventional,
Radiation 
quality
RBE
5 R‘s
Reassortment
Repair / chrom. instab.
Reoxygenation
Repopulation: eliminated
Radiosensitivity
Special 
effects ?
Cytokines
Vascular
Immune
Irradiated
volume
S.o.E.
Late NT 
effects
Fig. 4 Schematic overview of biological effects contributing to the efficacy of IORT with high single doses. RBE: relative biologic effectiveness;
S.o.E.: Sphere of Equivalence; NT: normal tissue
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fractionated RT. The increased RBE should be taken into
account for LEX. Although the L-Q model predicts that
RBE should decrease as the dose per fraction increases
[20], evidence suggests that this may not be true for
low-LET radiations. Conversely, this also implies that a
slightly reduced RBE of high-energy electrons cannot be
excluded even at high doses although this may be cell-
type dependent. However, in clinical practice, RBE = 1
relative to high-energy X-rays is usually assumed for
fractionated RT with electrons and more studies would
be required to determine if a lower value should be
applied for IOERT with single doses in the range of 10–
20 Gy. A number of factors may contribute to making
single-dose IORT biologically feasible in spite of being a
departure from the established fractionated schemes
based on the five R’s of radiotherapy. Published and pre-
sented evidence supports a hypothesis that saturation of
the repair system leads to increasing genomic instability
that may contribute to inactivate tumour cells as the
dose per fraction is increased beyond the dose range
normally studied in vitro. Furthermore, IORT performed
during surgery eliminates repopulation of residual
tumour cells in the tumour bed during the time for
wound healing before starting and possibly during con-
ventionally fractionated EBRT. Thus some patients are
likely to have very few residual tumour cells which
may be cured even by moderate doses to the tumour
bed. In addition, the high dose close to the applicator
surface of LEX is predicted to be more efficient than
the uniform dose from an external beam, thus partly
compensating the lower doses at larger depth in the
tumour bed. Together with increased tolerance of the
normal tissue to high local doses owing to the vol-
ume effect, the combination of these factors work in
favour of making IORT more efficient than expected
from clinical experience with EBRT. Whether special
effects of high single doses also contribute to the effi-
cacy will require further experimental and clinical
studies.
Endnotes
1After acceptance of the present manuscript, an ana-
lysis of the effect of overall treatment time has been
published by the START Trial Management Group
[150]. Based on the combined cohorts of all three
START trials (START pilot, START A, and START B),
the effect of overall treatment time on loco-regional
control was estimated at 0.60 Gy/day. Although inde-
pendent validation of this observation is needed, the
time effect is higher than the rough estimate made here
suggesting that the potential benefit of IORT in elimin-
ating the repopulation associated with fractionated
WBRT might be even larger than 28 Gy.
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